CD31/PECAM-1 Antibody (C31.3)

Cluster of differentiation (CD31), Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1), is a 30kDa type I transmembrane glycoprotein expressed by endothelial cells, platelets, leukocytes and some lymphocytes (e.g., B and T-cell subsets). Structurally, PECAM-1 consists of six extracellular immunoglobulin-like domains which serve to support various functions including homophilic binding, maintaining high expression of PECAM-1 within endothelial intercellular junctions, and supporting endothelial cell migration (1,2). PECAM's homophilic binding underscores its role in vascular barrier integrity and leukocyte trans-endothelial movement. However, PECAM may also engage in heterophilic interactions with molecules such as glycosaminoglycans (GAG), integrin alpha 5 beta 3, CD38 in lymphocytes and CD177/PR3 in neutrophils (2).

PECAM's intracellular cytoplasmic domain consists of a sequence of 118 amino acids and contains serine and tyrosine (also referred to as immunoreceptor tyrosine-based inhibitory motifs-ITIMs) residues, which may be phosphorylated upon cellular stimulation (3). ITIMs are phosphorylated by Src-family kinases and non-Src family kinases (e.g., Csk), leading to a conformational change which supports interactions with Src homology 2 (SH2) domain containing proteins such as protein-tyrosine phosphatase, SHP-2 (1,2). Formation of SHP-2/PECAM-1 complexes induces endothelial cell migration through the dephosphorylation of focal adhesion kinase and regulation of RhoA activity (1). Signaling downstream of ITIM tyrosine phosphorylations also plays a role in PECAM's anti-apoptotic activity, a function which is independent of its interaction with SHP-2. In platelets and leukocytes, phosphorylation of PECAM's cytosolic domain is inhibitory, preventing their activation.

References

1. Lertkiatmongkol, P., Liao, D., Mei, H., Hu, Y., & Newman, P. J. (2016). Endothelial functions of PECAM-1 (CD31). Current Opinion in Hematology. https://doi.org/10.1097/MOH.0000000000000239.Endothelial

2. Privratsky, J. R., & Newman, P. J. (2014). PECAM-1: Regulator of endothelial junctional integrity. Cell and Tissue Research. https://doi.org/10.1007/s00441-013-1779-3

3. Newman, P. J., & Newman, D. K. (2003). Signal transduction pathways mediated by PECAM-1: New roles for an old molecule in platelet and vascular cell biology. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.ATV.0000071347.69358.D9

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 4 applications: ICC/IF, IHC-Fr, IHC-P, WB.

Showing Publications 1 - 7 of 7.

Publications using NBP2-15202	Applications	Species
Poels, K, Schnitzler, J G Et al. Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability. Front Cell Dev Biol 2020-12-08 [PMID: 33282864] (WB, Human)	WB	Human
Luu W, Bjork J, Salo E et al. A novel strategy to engineer pre-vascularized 3-dimensional skin substitutes to achieve efficient, functional engraftment Sci Rep 2019-05-24 [PMID: 31127144] (IHC-P, Human)	IHC-P	Human
Giatromanolaki A, Koukourakis MI, Sivridis E et al. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. Br J Cancer. 2012-09-25 [PMID: 22910317]
Jernman J, Valimaki MJ, Louhimo J et al. The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours. Neuroendocrinology. 2012-01-01 [PMID: 22327359] (IHC-P) Details: IHC (paraffin): Tables 1-3 (gastrointestinal neuroendocrine neoplasms).	IHC-P
Gratzinger D, Zhao S, West R et al. The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol. 2009-02-01 [PMID: 19141387] (IHC-P) Details: IHC (P): Figs 2B (myocardial vasculature), 2D (fetal myocardial vasculature). Various other tissues were used in this study and results described.	IHC-P
Govender D, Harilal P, Dada M, Chetty R. CD31 (JC70) expression in plasma cells: an immunohistochemical analysis of reactive and neoplastic plasma cells. J Clin Pathol. 1997-06-01 [PMID: 9378815] (IHC-P) Details: IHC (paraffin): Fig 1 (chronic inflammatory infiltrate), Fig 2 (multiple myeloma).	IHC-P
Parums DV, Cordell JL, Micklem K et al. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol. 1990-09-01 [PMID: 2212067] (WB, IHC-Fr, ICC/IF) Details: WB: Fig 1 (spleen and platelets); Immunocytochemistry: Fig 2 (blood smear); IHC (frozen): Fig 3 (tonsil); IHC (paraffin): Figs 4-7 (various tissues).	WB, IHC-Fr, ICC/IF

Array NBP2-15202

• CD31/PECAM-1 Antibodies
• CD31/PECAM-1 Antibody Pair
• CD31/PECAM-1 ELISA Kits
• CD31/PECAM-1 Lysate
• CD31/PECAM-1 Protein
• CD31/PECAM-1 Proteins and Enzymes
• CD31/PECAM-1 ELISAs